Search results for melanoma
AI & Enterprise
Older Google model beats latest GPT and Claude in skin cancer test
Latest general-purpose AI models recorded lower accuracy than Google’s Inception v3 image recognition model released in 2016 in a skin lesion diagnosis experiment. Researchers compared GPT-6 Astra, Claude Fable 5.1 and Inception v3 using 200 lesion images split between cases needing treatment and those requiring no action. Inception v3 led overall and in melanoma identification. The study said differing training conditions limited interpretation and larger validation and safety assessments are needed for clinical use.
Industry
Moderna, Merck personalised mRNA cancer vaccine cuts melanoma recurrence or death risk by 42%
A personalised mRNA cancer vaccine being co-developed by Moderna and Merck reduced the risk of recurrence or death in melanoma patients by 42%, the report said. In a phase 3 trial involving 1,137 patients who had tumours removed by surgery, those receiving the vaccine intismeran with Merck\'s Keytruda outperformed a Keytruda-plus-placebo group. The companies are discussing approval procedures with regulators, with detailed results due at a European oncology meeting in Madrid.
AI & Enterprise
AI fear-battered stocks revive in August U.S. market rebound lineup
In August, U.S. stocks that had been weighed down by Wall Street’s bearish narratives rebounded sharply, CNBC reported. Jim Cramer said worries over AI threats, slower growth and worsening conditions were overturned by earnings and shifts in positioning. Moderna surged after reporting promising results for an experimental melanoma vaccine with Merck. Enterprise software names rebounded as a high-leverage hedge fund unwound bets. Other gainers included Gartner, Newmont, Paramount Skydance, Super Micro Computer, Sandisk and Coinbase.
